A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus

Pharmacotherapy

Volumn 29, Issue 11, 2009, Pages 1280-1288

  Sullivan, Sean D ^a   Alfonso Cristancho, Rafael ^a   Conner, Chris ^b   Hammer, Mette ^c   Blonde, Lawrence ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NOVO NORDISK INC   (United States)

^c NOVO NORDISK A S   (Denmark)

^d Ochsner Children's Health Center   (United States)

Author keywords

Complications; CORE diabetes model; Cost; Glimepiride; Liraglutide; Monotherapy; Risk factors; Survival; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; LIRAGLUTIDE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

BLOOD GLUCOSE; BLOOD PRESSURE; COHORT STUDIES; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MODELS, THEORETICAL; MORBIDITY; SULFONYLUREA COMPOUNDS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70350520817     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.11.1280     Document Type: Article

References (57)

1. Zimmet P, Shaw J, Alberti KG. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 2003;20:693-702. (Pubitemid 41701460)
2. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med 1997;14:S1-85. (Pubitemid 28020378)
3. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care 1998;21:1414-1431
4. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:1-20.
5. World Health Organization. Diabetes, fact sheet no. 312, 2008. Available from http://www.who.int/mediacentre/factsheets/ fs312/en/. Accessed July 10, 2008.
6. Copeland KC, Becker D, Gottschalk M, Hale D. Type 2 diabetes in children and adolescents: risk factors, diagnosis, and treatment. Clin Diabetes 2005;23:181-185 (Pubitemid 41464519)
7. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 2002;25:476-481 (Pubitemid 41103339)
8. Centers for Disease Control and Prevention. Prevalence and incidence. In: 1999 diabetes surveillance report. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2004.
9. Nichols GA, Brown JB. The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care 2002;25:482-486
10. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25:1017-1038
11. Gilmer TP, O'Connor PJ, Rush WA, et al. Predictors of health care costs in adults with diabetes. Diabetes Care 2005;28:59-64. (Pubitemid 40095783)
12. Gandra SR, Lawrence LW, Parasuraman BM, et al. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. J Manag Care Pharm 2006;12:546-554
13. Geiss LS, Pan L, Cadwell B, et al. Changes in incidence of diabetes in U.S. adults, 1997-2003. Am J Prev Med 2006;30:371-377
14. Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999;82:1519-1522
15. Ogden CL, Fryar CD, Carroll MD, et al. Mean body weight, height, and body mass index, United States 1960-2002. Adv Data 2004;347:1-17.
16. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study. Circulation 1983;67:968-977
17. Han TS, Tijhuis MAR, Lean MEJ, Seidell JC. Quality of life in relation to overweight and body fat distribution. Am J Public Health 1998;88:1814-1820
18. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 2007;33:1014-1029
19. . Narayan K, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006;29:2114-2116
20. Mainous AG, Baker R, Koopman RJ, et al. Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way. Diabetologia 2007;50:934-940 (Pubitemid 46559242)
21. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
22. Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002;287:360-372 (Pubitemid 34229553)
23. United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
24. Kahn SE, Haffner SM, Heise MA, et al, for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443 (Erratum in N Engl J Med 2007;356:1387-8.)
25. Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007;27:1102-1110 (Pubitemid 47173656)
26. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-86
27. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) Diabet Med 2009;26:268-278
28. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009;32:84-90.
29. Garber A, Henry R, Ratner R, et al, for the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373;473-481
30. Zinman B, Gerich J, Buse J, et al. Effect of the GLP-1 analog liraglutide on glycemic control and weight reduction in patients on metformin and rosiglitazone: a randomized double-blind placebo-controlled trial [abstract]. Diabetologia 2008;51(suppl 1):S359.
31. Russell-Jones D, Vaag A, Schmitz O, et al. Significantly better glycaemic control/weight reduction with human GLP-1 analogue liraglutide, than with insulin glargine: all as add-on to metformin + sulphonylurea in type 2 diabetes [abstract]. Diabetologia 2008;51(suppl 1):S68.
32. Blonde L, Rosenstock J, Sesti G, et al. Liraglutide: superior glycemic control vs exenatide when added to metformin and/or sulfonylurea in type 2 diabetes [abstract]. Can J Diabetes 2008;32 (suppl): A107.
33. Minshall ME, Oglesby AK, Wintle ME, Valentine WJ, Roze S, Palmer AJ. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health 2008;11:22-33. (Pubitemid 351160873)
34. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006;144:465-474
35. Brändle M, Herman WH. The CORE diabetes model. Curr Med Res Opin 2004;20(suppl 1):S1-3.
36. Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004;20(suppl 1):S5-26. (Pubitemid 39349905)
37. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(suppl 1):S27-40. (Pubitemid 39349906)
38. Palmer AJ, Roze S, Valentine WJ, et al. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE diabetes model. Curr Med Res Opin 2004;20(suppl 1):S53-8. (Pubitemid 39349908)
39. Palmer AJ, Roze S, Valentine WJ, et al. What impact would pancreatic β-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE diabetes model. Curr Med Res Opin 2004;20(suppl 1):S59-66. (Pubitemid 39349909)
40. Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injections for the treatment of type 1 diabetes in the UK. Diabet Med 2005;22:1239-1245 (Pubitemid 41224186)
41. Watkins JB, Minshall ME, Sullivan SD. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience. J Manag Care Pharm 2006;12:726-735
42. Tarn T, Smith M. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004;1:5-15.
43. Fleming T, ed. 2006 drug topics red book, 11th ed. Montvale, NJ: Thomson PDR, 2006.
44. Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001;27:347-351 (Pubitemid 32290859)
45. Anonymous. St. Anthony's DRG guidebook. A comprehensive resource to the DRG classification system, 17th ed. Florence, KY: Delmar Learning, 2001.
46. Shearer A, Scuffham P, Gordois A, Oglesby A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care 2003;26:2305-2310 (Pubitemid 36993317)
47. Gæde P, Lund-Andersen H, Parving H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591 (Pubitemid 351214285)
48. Gerstein HC, Miller ME, Byinton RP, et al, for the Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
49. Patel A, MacMahon S, Chalmers J, et al, for the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
50. Duckworth W, Abraira C, Moritz T, et al, for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
51. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772
52. American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-2265 (Pubitemid 39167200)
53. WellPoint. Health technology assessment guidelines: drug submission guidelines for new products, new indications, and new formulations (updated September 2008). The WellPoint outcomes based formulary, WellPointNextRx. Available from https://www.wellpointnextrx.com/shared/noapplication/f1/s0/t 0/pw-ad080613.pdf. Accessed January 2, 2009.
54. Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the fourth Mount Hood challenge meeting. Diabetes Care 2007;30:1638-1646
55. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy - a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
56. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187-192
57. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008;31:S12-54.